REHOVOT, Israel-Rosetta Genomics Ltd. and the New York University School of Medicine have expanded their collaboration to include congenital heart disease. Applying Rosetta Genomics' microRNA extraction protocols from various body fluids and NYU School of Medicine's experience in this field, they will screen for specific microRNA biomarkers and signatures that may be used to diagnose and target congenital heart disease in newborns. "As a cutting-edge research institution, NYU School of Medicine is a close collaborator of Rosetta Genomics in the microRNA field, and I am confident this collaboration will enhance our understanding of the link between microRNAs and various heart conditions," notes Amir Avniel, CEO and president of Rosetta Genomics.